2130869-18-8
Chemical Structure
Mal-PEG2-VCP-Eribulin
- CAS No.: 2130869-18-8
- Formula:C70H99N7O21
- Molecular Weight:1374.57
InChIKey: ODAGJGZILCZEBN-LHGNNKGASA-N
SMILES: C=C1C[C@@]2([H])O[C@@]1([H])CC[C@]3([H])O[C@](C([C@H](C)C3)=C)([H])C[C@@]4([H])[C@]([C@@H](OC)[C@@H](C[C@H](O)CNC(OCC5=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCOCCOCCN6C(C=CC6=O)=O)=O)=O)=O)C=C5)=O)O4)([H])CC(C[C@]7([H])O[C@]8([H])[C@]9([H])O[C@@]%10(O[C@@]%11([H])[C@@](O[C@]9([H])[C@@]%11([H])O[C@@]8([H])CC7)([H])C%10)CC2)=O
Biological Activity: Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mal-PEG2-VCP-Eribulin | 99.79% | Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.
- [2]. Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505. [Content Brief]
- [3]. Watanabe K, et al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4;10(2):161-174. [Content Brief]
